


CLAIMS

1. A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein


R^2 is (C₁-C₃)alkyl, hydroxy(C₁-C₃)alkyl, halo(C₁-C₃)alkyl, benzyl, (C₁-C₃)alkoxy(C₁-C₃)alkyl, tetrahydropyranyl, or -CH₂-tetrahydropyranyl;

R^3 and R^4 are each independently hydrogen or methyl;

Cy^1 is phenyl or pyridyl, each substituted with (C₁-C₃)alkylsulfonyl; and


Cy^2 is hydrogen, halo(C₁-C₃)alkyl, cyclohexyl, or tetrahydropyranyl, wherein the cyclohexyl and tetrahydropyranyl are each optionally substituted with one or more groups selected from halo(C₁-C₃)alkyl and C₁-C₃(alkoxy).

2. The compound of Claim 1, wherein the compound is of the Formula:




or a pharmaceutically acceptable salt thereof.

3. The compound of Claim 1 or 2, wherein the compound is of the Formula:



or a pharmaceutically acceptable salt thereof.


4. The compound of any one of Claims 1 to 3, wherein the compound is of the Formula:



or a pharmaceutically acceptable salt thereof.

5. The compound of any one of Claims 1 to 4, wherein Cy² is cyclohexyl or tetrahydropyranyl, each of which are optionally substituted with one or more groups selected from halo(C₁-C₃)alkyl and C₁-C₃(alkoxy).

6. The compound of any one of Claims 1 to 5, wherein the compound is of the Formula:



or a pharmaceutically acceptable salt thereof, wherein


X is CH or N;

Y¹ is O and Y² is CH₂, Y¹ is CH₂ and Y² is O, or Y¹ and Y² are each CH₂;

R⁹ is halo(C₁-C₃)alkyl; and


R¹⁰ is (C₁-C₃)alkylsulfonyl...

7. The compound of any one of Claims 1 to 6, wherein the compound is of the Formula:




or a pharmaceutically acceptable salt thereof.






8. The compound of any one of Claims 1 to 7, wherein the compound is of the Formula:





or a pharmaceutically acceptable salt thereof.


9. The compound of any one of Claims 1 to 8, wherein R² is methyl, ethyl, benzyl, or isopropyl.
10. The compound of any one of Claims 1 to 9, wherein R² is ethyl or isopropyl.
11. The compound of any one of Claims 6 to 10, wherein R⁹ is CF₃; and R¹⁰ is SO₂Et or SO₂Me.
12. The compound of Claim 1, wherein the compound is selected from
















and



13. The compound of Claim 1, wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A therapeutically effective amount of the compound according to any one of Claims 1 to 13, or the pharmaceutically acceptable salt thereof, for use in therapy.
16. Use of a therapeutically effective amount of the compound according to any one of Claims 1 to 13, or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder selected from asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, urticaria, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, adipose tissue-associated inflammation, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age related macular degeneration, dry eye, uveitis, Guillain-Barré syndrome, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, Graves' disease, scleritis, major depression, seasonal affective disorder, PTSD, bipolar disorder, autism, epilepsy, Alzheimer's, CNS disorders associated with altered sleep and/or circadian rhythms, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyocitis, graft versus host disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuromyelitis, juvenile idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyposis, and cancer.